chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Body temperature, Diarrhoea, Heart rate, Hypertension
Clinical narrative: blood pressure 154/80; Temperature today at 12:25 pm 100.5Temperature today at 12:48pm 101.2; body aches; extremely thirsty and cant get enough to drink; a little tingling around the lips for just a short time and then it went away; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8727) via an unspecified route of administration in the right arm on 10Apr2021 at 12:00 (at the age of 69-year-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer since 1999, IVP(Intravenous pyelogram) allergy, surgery in 2020, lumpectomy on an unspecified date in Feb2017, lymph node biopsy on 31Mar2021 and COVID-19 from unknown date to an unknown date. Concomitant medications included atenolol (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and amlodipine besilate (MANUFACTURER UNKNOWN) for unknown indications from unknown date. The patient previously took tetanus vaccine toxoid (MANUFACTURER UNKNOWN), pentosan polysulfate sodium (ELMIRON), atorvastatin calcium (LIPITOR), rosuvastatin calcium (CRESTOR), methotrexate(MANUFACTURER UNKNOWN), boric acid (MANUFACTURER UNKNOWN), sulfamethoxazole, trimethoprim(SEPTRA) and experienced allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 12:45, the patient experienced a little tingling around the lips for just a short time and then it went away and at night had diarrhea and also on 11Apr2021 (next day) morning. On 11Apr2021, the patient was extreme thirsty and cannot get enough to drink, body aches and at 12:25, the patient had temperature of 100.5(fever), at 12:47, the patient had a blood pressure of 154/80(high blood pressure) and at 12:48, temperature of 101.2. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other health care professional office/clinic visit and emergency room/department or urgent care. On 11Apr2021, the patient underwent body temperature, blood pressure, heart rate tests and resulted with a temperature of 100.5 and 101.2(unspecified units), blood pressure of 154/80(unspecified units) and heart rate of 68(unspecified units). The clinical outcome of the event tingling lips was recovered on 10Apr2021, while that of diarrhea, body aches, extreme thirsty, temperature of 100.5, 101.2 and blood pressure of 154/80 were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Paraesthesia oral, Pyrexia, Thirst
Clinical narrative: blood pressure 154/80; Temperature today at 12:25 pm 100.5Temperature today at 12:48pm 101.2; body aches; extremely thirsty and cant get enough to drink; a little tingling around the lips for just a short time and then it went away; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8727) via an unspecified route of administration in the right arm on 10Apr2021 at 12:00 (at the age of 69-year-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer since 1999, IVP(Intravenous pyelogram) allergy, surgery in 2020, lumpectomy on an unspecified date in Feb2017, lymph node biopsy on 31Mar2021 and COVID-19 from unknown date to an unknown date. Concomitant medications included atenolol (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and amlodipine besilate (MANUFACTURER UNKNOWN) for unknown indications from unknown date. The patient previously took tetanus vaccine toxoid (MANUFACTURER UNKNOWN), pentosan polysulfate sodium (ELMIRON), atorvastatin calcium (LIPITOR), rosuvastatin calcium (CRESTOR), methotrexate(MANUFACTURER UNKNOWN), boric acid (MANUFACTURER UNKNOWN), sulfamethoxazole, trimethoprim(SEPTRA) and experienced allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 12:45, the patient experienced a little tingling around the lips for just a short time and then it went away and at night had diarrhea and also on 11Apr2021 (next day) morning. On 11Apr2021, the patient was extreme thirsty and cannot get enough to drink, body aches and at 12:25, the patient had temperature of 100.5(fever), at 12:47, the patient had a blood pressure of 154/80(high blood pressure) and at 12:48, temperature of 101.2. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other health care professional office/clinic visit and emergency room/department or urgent care. On 11Apr2021, the patient underwent body temperature, blood pressure, heart rate tests and resulted with a temperature of 100.5 and 101.2(unspecified units), blood pressure of 154/80(unspecified units) and heart rate of 68(unspecified units). The clinical outcome of the event tingling lips was recovered on 10Apr2021, while that of diarrhea, body aches, extreme thirsty, temperature of 100.5, 101.2 and blood pressure of 154/80 were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 17Mar2021 at 08:30, as a single dose for COVID-19 immunisation. Medical history included mild hypertension. The patient did not have any known allergies. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and alprazolam (MANUFACTURER UNKNOWN), both started on an unknown date for unspecified indication. The patient previously took two doses of shingles vaccinations in 2018. Prior to the vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021, 1.5 weeks after vaccination, the patient experienced shingles. Therapeutic measures were taken as a result of shingles which included treatment with antiviral medication. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event shingles was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Dizziness, Fatigue, Malaise
Clinical narrative: tiredness; chilly; nausea; feeling unwell; dizziness; "weakness worst"; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 31Mar2021 at 10:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included vertigo. The patient had no known allergies. The patient received unspecified medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 09:00, the patient experienced tiredness, chilly, nausea, feeling unwell, dizziness and weakness (worst). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of tiredness, chilly, nausea, feeling unwell, dizziness and weakness (worst) which included treatment with MECLIZINE. The clinical outcome of the events tiredness, chilly, nausea, feeling unwell, dizziness and "weakness worst" were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: tiredness; chilly; nausea; feeling unwell; dizziness; "weakness worst"; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 31Mar2021 at 10:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included vertigo. The patient had no known allergies. The patient received unspecified medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 09:00, the patient experienced tiredness, chilly, nausea, feeling unwell, dizziness and weakness (worst). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of tiredness, chilly, nausea, feeling unwell, dizziness and weakness (worst) which included treatment with MECLIZINE. The clinical outcome of the events tiredness, chilly, nausea, feeling unwell, dizziness and "weakness worst" were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Hyperaesthesia, Pyrexia, SARS-CoV-2 test
Clinical narrative: Hypersensitive nerves (putting on clothes, or rubbing of skin is painful); Fever; Chills; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 10Apr2021 at 10:30 (at the age of 22-years-old) as a single dose for COVID-19 immunization. Medical history was not reported. Concomitant medications included escitalopram oxalate (LEXAPRO) 15 mg and bupropion (MANUFACTURER UNKNOWN) 150 mg; both for an unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 27Mar2021 at 10:30 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 10Apr2021 at 22:00, the patient experienced hypersensitive nerves (putting on clothes, or rubbing of skin is painful), fever and chills. On 07Apr2021 (post vaccination), the patient underwent PCR (nasal swab/rapid antigen) and the result was negative. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events, hypersensitive nerves (putting on clothes, or rubbing of skin is painful), fever and chills was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Hypoaesthesia
Clinical narrative: Left side of face feels slightly numb/numbness started in jaw and felt like it moved up into cheeks and towards head; Headache; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 2613) via an unspecified route of administration in the left arm on 11Apr2021 at 12:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient had no past medical history. The patient had no known allergies to medications, food, or other products.  Concomitant medication included birth control (MANUFACTURER UNKNOWN); taken on an unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 13:45, the patient experienced left side of face feels slightly numb. The numbness started in jaw and felt like it moved up into cheeks and towards head. This feeling was getting less intense as times went on, but still felt it five hours she received the vaccine. The patient also had a headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events left side of face feels slightly numb/ numbness started in jaw and felt like it moved up into cheeks and towards head and headache were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness
Clinical narrative: This is a spontaneous report from a noncontactable consumer (patient). A 33-year-old (non-pregnant) female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine, batch/lot# unknown), at the age of 33, via an unspecified route of administration, right arm, on an unknown date, single dose, for COVID-19 immunisation. Medical history and concomitant medication not reported. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine, batch/lot# unknown), via an unspecified route of administration, on an unknown date, single dose, for COVID-19 immunisation. The patient is allergic to nuts. Prior to vaccination, it was unknown whether patient was diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 2, 2021, patient felt like she had flu and had swollen arm pits (lymphadenopathy). The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of felt like flu and swollen arm pits recovered on an unknown date in Apr 2021. No follow-up attempts possible. Information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Herpes zoster, Mucosal disorder
Clinical narrative: Mucous; Headache; shingles on head and forehead; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727), via an unspecified route of administration in the left arm on 26Mar2021 at 11:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included cyclical neutropenia immune deficiency. The patient did not have any allergies to medications, food or other products. Concomitant medications were not provided. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 12:00, the patient experienced mucous, headache and then shingles on head and forehead. Shingles diagnosed by urgent care. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of shingles which included treatment with antiviral medicine. The clinical outcome of the events mucous, headache and then shingles on head and forehead were not resolved at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Dry skin, Nausea, Pain in extremity, Weight decreased
Clinical narrative: Nauseated time onset still going; Sore arm; Loss of appetite; Dry skin patch; Weight loss of 2 lbs; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 02Apr2021 at 12:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had known allergies to collins and also had seasonal allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021 at 14:15 the patient experienced nauseated time onset was still going two days later, sore arm, loss of appetite, dry skin patch and weight loss of 2 lbs. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of reported events. The clinical outcome of the events nauseated time onset was still going two days later, sore arm, loss of appetite, dry skin patch and weight loss were all not recovered at the time of this report.  No follow-up attempts are needed; information about lot\batch number cannot be obtained.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: painful swelling of the lymph node in my right armpit after my second dose (which was in my right arm); painful swelling of the lymph node in my right armpit after my second dose (which was in my right arm); This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER87729) via an unspecified route of administration in the right arm on 09Apr2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included depression (reported as depressing), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), attention deficit disorder (ADD) and scoliosis. The patient had sensitivity to nickel (nickel allergy) and pollen allergy (pine pollen and cottonwood pollen). The patient had received other medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 19Mar2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 06:00, the patient experienced painful swelling of the lymph node in her right armpit after her second dose (which was in her right arm). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events painful swelling of the lymph node in right armpit after second dose (which was in right arm) was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Pain
Clinical narrative: Pain level 9 in right shoulder; radiating to the neck; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FN6197) via an unspecified route of administration in the left arm on 12Mar2021 at 09:30 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history included stomach cancer and bladder cancer. The patient had no allergies to medications, food, or other products. Concomitant medications included imatinib mesilate (GLEEVEC) for cancer treatment from an unknown date. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9809) via an unspecified route of administration in the arm left on 19Feb2021 at 13:15 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021, the patient experienced pain level 9 in the right shoulder and was radiating to the neck. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event pain level 9 in the right shoulder and radiating to the neck was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Insomnia, SARS-CoV-2 test
Clinical narrative: Lack of sleep; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 24Feb2021 at 14:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history not reported. Concomitant medication included chemotherapy from an unknown date, for unknown indication and unknown if ongoing. The patient had no known allergies to food, medications or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Feb2021 at 23:00, the patient experienced lack of sleep. On an unknown date, the patient underwent SARS Cov2 test (nasal swab test) and the result was unknown. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of reported event. The clinical outcome of the event lack of sleep was recovered on an unknown date in 2021 at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Started to have hives; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534, expiration date: 31Jul2021) via an unspecified route of administration in the right arm on 05Apr2021 at 12:15 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. The patient reported that she had no known chronic conditions. It was unknown if the patient had any allergies to medications, food, or other products. The patient did not receive any medication within two weeks of the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 06Apr2021 at 19:00, the patient started to have hives. The patient reported that she has had hives every night since. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the event and included treatment with 5 mg of cetirizine HCl (cetirizine hydrochloride). The clinical outcome of the event hives was unknown at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Pain in extremity, Pyrexia
Clinical narrative: Chills; 100.5 fever started 12 hours after shot; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 09Apr2021 at 11:30(at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included ulcerative colitis and type 2 diabetes mellitus from an unknown date. Concomitant medications included azathioprine (IMURAN), mesalazine (MESALAMINE), atorvastatin calcium (LIPITOR) and glucosamine (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 19Mar2021 at 11:30(at the age of 56-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 23:30 the patient experienced chills and 100.5 fever started 12 hours after shot. Sore arm, fever went down after 36 hours, but got back up in the afternoon, about 42 hours after shot. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events chills, 100.5 fever and sore arm was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Herpes zoster
Clinical narrative: Shingles; burning right hip; tingling pain in the right hip; This is a spontaneous report from a contactable physician. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: el9264) via an unspecified route of administration in the left arm on 09Feb2021 at 11:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient's medical history included sulfonamide allergy. Concomitant medications included vitamin D3 2000iu (MANUFACTURER UNKNOWN) and b complex (MANUFACTURER UNKNOWN), both since unknown dates and for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: el1283) via an unspecified route of administration in the left arm on 12Jan2021 at 12:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 28Mar2021 at 14:00, the patient experienced burning tingling pain in the right hip. On 04Apr2021, the patient experienced shingles. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken for the reported events. The clinical outcomes of the events burning right hip, tingling pain in the right hip and shingles were recovering at the time of this report.    No follow-up attempts are possible. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 at 12:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included none. Patient had unspecified known allergies. Concomitant medications were not reported. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Feb2021 at 14:15 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Mar2021 the patient experienced consistent headaches and tiredness. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events consistent headaches and tiredness was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Vaccination site pain
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 75-year-old female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER8730), at the age of 75, via an unspecified route of administration, right arm, on Mar 31, 2021, at 11:00, single dose, for COVID-19 immunisation. Medical history included high blood pressure, arthritis and COVID-19. The patient did not have a history of allergies to any food or medications or other products. Concomitant medications included Celebrex (celecoxib), Novasen (acetylsalicylic acid) and daily vitamins for an unknown indication, on an unknown date. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 75, via an unspecified route of administration, left arm, on Mar 10, 2021, at 11:00, single dose, for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, patient was diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. On Apr 2, 2021, patient experienced more tired than usual, seemed to be in fog at times and really sore at injection site at times (like someone was hitting the patient). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures taken for the events. The clinical outcome of more tired than usual, seemed to be in fog at times and really sore at injection site recovered with sequelae on an unknown date in Apr 2021. No follow-up attempts are needed. Information about lot/batch number cannot be obtained. No further information expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia, Paraesthesia oral
Clinical narrative: The right side of  face (ear, cheek, jaw, gland, tongue slightly), got tingly; The right side of my face (ear, cheek, jaw, gland, tongue slightly), got tingly/number a hour after my second shot. I took two bendryl in case. Past4 hour mark still slightly numb but slightly better.; The right side of my face (ear, cheek, jaw, gland, tongue slightly), got tingly; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0153), via an unspecified route of administration in the left arm on 11Apr2021 at 15:15 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had reported seasonal allergies to (pollen and mold spores). Concomitant medications included loratadine (CLARITIN) from unknown date for unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6956), via an unspecified route of administration in the left arm on 21Mar2021 at 16:00 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. The patient previously received pertussis vaccine (MANUFACTURER UNKNOWN) on unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 16:15, the patient experienced the right side of face (ear, cheek, jaw, gland, tongue slightly), got tingly/numb a hour after the second shot. The patient took two bendryl and after 4 hours still patient felt slightly numb but slightly better and there was no facial drooping. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with bendryl.  The clinical outcome of the events the right side of face (ear, cheek, jaw, gland, tongue slightly), got tingly/numb a hour after the second shot, past 4 hour mark still slightly numb but slightly better were resolving at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: Severe bloody noses around 28 hours after first dose; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: UNKNOWN) via an unspecified route of administration in the right  arm on 10Apr2021 at 12:45 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history included attention deficit hyperactivity disorder (ADHD), bipolar II disorder, depression, polycystic ovarian syndrome(PCOS), gastroesophageal reflux disease (GERD).The patient had known allergy to insect bite (bee venom). The patient had other medications received in two weeks which had not enough room to list. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 15:45 ,the patient experienced severe bloody noses around 28 hours after first dose. The patient did not have any history of prior bloody noses. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event severe bloody noses around 28 hours after first dose was resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Nausea, Pruritus
Clinical narrative: Red hot itchy raised circle above vaccination area; Red hot itchy raised circle above vaccination area; quarter sized.; Headache; Fever of 101; Nausea; Chills; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 09Apr2021 at 12:00(at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy and penicillin allergy. Concomitant medications included Botox, ibuprofen (MANUFACTURER UNKNOWN) and loratadine (CLARITIN) for unknown indication and from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021(at the age of 50 years old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021, the patient experienced a red hot itchy raised circle above the vaccination area; quarter-sized. The patient did experience side effects like headache, fever of 101, nausea, and chills. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events red hot itchy raised circle above the vaccination area, headache, fever of 101, nausea, and chills were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site erythema
Clinical narrative: Red hot itchy raised circle above vaccination area; Red hot itchy raised circle above vaccination area; quarter sized.; Headache; Fever of 101; Nausea; Chills; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 09Apr2021 at 12:00(at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy and penicillin allergy. Concomitant medications included Botox, ibuprofen (MANUFACTURER UNKNOWN) and loratadine (CLARITIN) for unknown indication and from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021(at the age of 50 years old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021, the patient experienced a red hot itchy raised circle above the vaccination area; quarter-sized. The patient did experience side effects like headache, fever of 101, nausea, and chills. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events red hot itchy raised circle above the vaccination area, headache, fever of 101, nausea, and chills were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: Breast pain, Nipple pain, Sleep disorder
Clinical narrative: Burning in breasts; Shooting pain in nipples; Keeping me up at night.; This is a spontaneous report from a contactable consumer, the patient. An unspecified aged non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the right arm on 07Apr2021 at 13:15 as a single dose for COVID-19 immunisation. Medical history included hypertension and chronic migraines. The patient had no known allergies to medications, food or other products. The patient received unspecified medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 13:45 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 07Apr2021 at 15:30, the patient experienced burning in breasts and shooting pain in nipples which was keeping the patient up at night. After the first day only in the right breast and had continued through day 4. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of reported events. The clinical outcomes of burning in breasts and shooting pain in nipples were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Rash, Urticaria
Clinical narrative: Rash; Hives; This is a spontaneous report from a contactable consumer, patient.  A 61-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2618) via an unspecified route of administration in the left arm on 20Mar2021 at 13:30 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included coronary artery disease and blood pressure high. The patient had no known allergies to medications, food, or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021, the patient experienced rash and hives. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events of rash and hives were not recovered at the time of report. Patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number:EP7533) via an unspecified route of administration in the left arm on 10Apr2021 (at the age of 61-year-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Joint swelling, Peripheral swelling, Pruritus
Clinical narrative: Joint pain in both arms; itching both arms intermittent till now; pain in hips; pain in knees; swelling in legs; swelling in right knee; This is a spontaneous report from a contactable consumer, the patient. A 78-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Enu20u) via an unspecified route of administration in the left arm on 17Mar2021 at 09:15 (at the age of 78-years-old) as a single dose for COVID-19 immunisation. Medical history included acid reflux (esophageal), cholesterol and blood pressure. The patient had known allergy to iodine, antibiotic, prednisone and sulphur. Concomitant medications included losartan (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN), prednisone (MANUFACTURER UNKNOWN), simvastatin (MANUFACTURER UNKNOWN) and acetylsalicylic acid (ASPIRIN); all from unknown dates and for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not received any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021, the patient experienced joint pain in both arms, itching both arms intermittent till now, pain in hips, pain in knees, swelling in legs, more prominent swelling in right knee. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the event of joint pain in both arms, itching, pain in hip, pain in knees, swelling of legs and swelling in right knee was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: Blurred short (reading) distance; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 09Apr2021 at 13:15 (at the age of 39-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient had no known drug allergies. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 15:00, the patient experienced blurred short (reading) distance. Over the course of 2-3 days, clear sight has returned. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. It was unknown whether the patient received any treatment for the event. The clinical outcome of the event blurred short (reading) distance was resolving at the time of reporting.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Mouth ulceration, Pain in extremity
Clinical narrative: Intense arm pain; Mouth ulcer; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EIN 0151) via an unspecified route of administration in the left arm on 09Apr2021 at 11:00 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no food and drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 10Apr2021 at 03:00, the patient experienced intense arm pain and mouth ulcer. It was unknown whether any therapeutic measures were taken as a result of the events. The clinical outcome of the events intense arm pain and mouth ulcer was not resolved at the time of the report.   No follow-up attempts are needed. No further information is expected.